Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.
Research article published in European heart journal (2013)
Abstract
Decision making with regard to thromboprophylaxis should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient. As a consequence, a crucial part of atrial fibrillation (AF) management requires the appropriate use of thromboprophylaxis, and the assessment of stroke as well as bleeding risk can help inform management decisions by clinicians. The objective of this review article is to provide an overview of stroke and bleeding risk assessment in AF. There would be particular emphasis on when, how, and why to use these risk stratification schemes, with a specific focus on the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)], CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 and sex category (female)], and HAS-BLED [hypertension (i.e. uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR (if on warfarin), elderly (e.g. age >65, frail condition), drugs (e.g. aspirin, NSAIDs)/alcohol concomitantly] risk scores.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.
Why This Matters for Hirudotherapy
This review article provides an overview of stroke and bleeding risk assessment in atrial fibrillation, focusing on the CHADS2, CHA2DS2-VASc, and HAS-BLED risk stratification schemes to guide thromboprophylaxis decisions. The abstract addresses anticoagulant decision-making frameworks but makes no reference to leeches, hirudotherapy, hirudin, or any leech-derived substance. There is no defensible leech-related relevance; the content is entirely within the domain of oral anticoagulant risk stratification for cardiac patients.
Citation
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.
Lip · European heart journal, 2013
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026